WITHDRAWN: Combined calcitonin gene-related peptide receptor antagonist, MK-8825, and caffeine as potential therapeutic target in the nitroglycerin-induced rat migraine model (MK-8825 and caffeine in migraine)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Source: Alexandria Journal of Medicine - Category: General Medicine Source Type: research

Related Links:

Condition:   Post-Dural Puncture Headache Interventions:   Drug: Oral Theophylline Anhydrous Tablet;   Drug: IV Neostigmine Methylsulfate + Atropine Sulphate Sponsor:   Damanhour Teaching Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Does galcanezumab, which has a long half-life of 27 days, demonstrate persistence of response or of adverse events after migraine treatment cessation?Headache
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Publication date: Available online 24 June 2019Source: The LancetAuthor(s): Maigeng Zhou, Haidong Wang, Xinying Zeng, Peng Yin, Jun Zhu, Wanqing Chen, Xiaohong Li, Lijun Wang, Limin Wang, Yunning Liu, Jiangmei Liu, Mei Zhang, Jinlei Qi, Shicheng Yu, Ashkan Afshin, Emmanuela Gakidou, Scott Glenn, Varsha Sarah Krish, Molly Katherine Miller-Petrie, W Cliff Mountjoy-VenningSummaryBackgroundPublic health is a priority for the Chinese Government. Evidence-based decision making for health at the province level in China, which is home to a fifth of the global population, is of paramount importance. This analysis uses data from the...
Source: The Lancet - Category: General Medicine Source Type: research
Not all headache disorders are the same. An excruciating, sudden-onset headache known as thunderclap headache (TCH) is a medical emergency, very different from more common headache disorders such as migraine and tension headache. If you develop TCH, you should call 911 or immediately go to the closest hospital. TCH is associated with a variety of causes, ranging from benign to potentially fatal. Urgent evaluation in an emergency setting is needed to quickly identify and treat any underlying condition. Diagnosing and treating secondary thunderclap headache When you arrive at the hospital, the medical team will want to confi...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Headache Health Source Type: blogs
ConclusionAlthough there is variability among Specialized Headache Units, the overall quality was generally better than in traditional neurology consultations in Spain.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
The Food and Drug Administration (FDA) on Fridayapproved Vyleesi (bremelanotide) to treat premenopausal women for acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD (classified as female sexual interest/arousal disorder inDSM-5) is characterized by low sexual desire that causes distress and cannot be explained by a comorbid physical or psychiatric illness, the side effects of substance use or medications, or severe relationship problems. Acquired HSDD means a woman has previously experienced sexual desire (it has not been a lifelong problem).“There are women who, for no known reason, have reduced se...
Source: Psychiatr News - Category: Psychiatry Tags: blood pressure female sexual interest/arousal disorder hypoactive sexual desire disorder naltrexone premenopausal women sexual dysfunction Vyleesi Source Type: research
(Natural News) Women suffer from migraines more often than men, but scientists didn’t know why. Until recently, a 30-year-long study in the Journal of Neuroscience revealed that women are more likely to have migraines than men because of the activity of a protein called calcitonin gene-related peptide (CGRP). Researchers at the University of Texas at...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
New Executive Team Will Oversee US Commercialization of FDA-Cleared Nerivio¬ô for Acute Treatment of Migraine NETANYA, Israel and MONTCLAIR, New Jersey, June 24, 2019 -- (Healthcare Sales &Marketing Network) -- Theranica Bioelectronics (Theranica), a b... Devices, Neurology, Personnel Theranica Bioelectronics, Nerivio, migraine, neuromodulation, electroceutical
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Last May, the Food and Drug Administration (FDA) approved Amgen and Novartis’ Aimovig, the first drug specifically designed to prevent chronic migraines, and offered new hope to the millions of Americans regularly weathering these debilitating headaches. Just months later came two other drugs in its class, Eli Lilly’s Emgality and Teva Pharmaceuticals’ Ajovy. About a year after Aimovig hit the market, patients and doctors are reporting dramatic successes thanks to these therapies. But as insurance horror stories accumulate, and manufacturer-sponsored financial assistance programs approach their end, patie...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Drugs Source Type: news
Title: AHA News: What Migraine Sufferers Need to Know About Stroke RiskCategory: Health NewsCreated: 6/21/2019 12:00:00 AMLast Editorial Review: 6/24/2019 12:00:00 AM
Source: MedicineNet Migraine General - Category: Neurology Source Type: news
More News: Caffeine | General Medicine | Genetics | Headache | Migraine | Nitroglycerin